Overview

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2023-03-30

Target enrollment:

Participant gender:

Summary

This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma

Phase:

Early Phase 1

Details

Lead Sponsor:

Hebei Senlang Biotechnology Inc., Ltd.

Treatments:

Cyclophosphamide
Fludarabine